Table 1.
Patient clinical characteristics.
| Normal | Cancer | DEG in snoRNA | p | ||
|---|---|---|---|---|---|
| (n = 12) | (n = 30) | No (n = 18) | Yes (n = 12) | ||
| Age (years) | 49.2 ± 11.6 | 49.9 ± 10.1 | 47.9 ± 11.4 | 52.8 ± 7.1 | 0.199 |
| FIGO stage 2018 | 0.627 | ||||
|
5 (16.7%) | 4 (22.2%) | 1 (8.3%) | ||
|
15 (50.0%) | 9 (50.0%) | 6 (50.0%) | ||
|
7 (23.3%) | 4 (22.2%) | 3 (25.0%) | ||
|
3 (10.0%) | 1 (5.6%) | 2 (16.7%) | ||
| Pathology | 0.374 | ||||
|
5 (16.7%) | 4 (22.2%) | 1 (8.3%) | ||
|
1 (3.3%) | 0 (0.0%) | 1 (8.3%) | ||
|
1 (3.3%) | 1 (5.6%) | 0 (0.0%) | ||
|
23 (76.7%) | 13 (72.2%) | 10 (83.3%) | ||
| Radiotherapy field | 0.464 | ||||
| Pelvis | 21 (70.0%) | 14 (77.8%) | 7 (58.3%) | ||
| Pelvis with paraaortic region | 9 (30.0%) | 4 (22.2%) | 5 (41.7%) | ||
| Hemoglobin (g/dl) | |||||
| Pretreatment | 12.1 ± 1.5 | 12.0 ± 1.5 | 12.2 ± 1.6 | 0.78 | |
| Second week during CCRT | 11.1 ± 1.4 | 11.3 ± 1.2 | 10.8 ± 1.7 | 0.336 | |
| Absolute lymphocyte count (cells/μL) | |||||
| Pretreatment | 1754 ± 470 | 1758 ± 451 | 1747 ± 518 | 0.95 | |
| First week after CCRT | 931 ± 393 | 929 ± 281 | 936 ± 546 | 0.966 | |
| Second week after CCRT | 511 [371; 632] | 575 [505; 661] | 384 [323; 466] | 0.008 | |
| Pretreatment tumor marker (ng/mL) | |||||
| Squamous cell carcinoma antigen | 3.7 [0.9; 16.6] | 2.2 [0.8; 4.8] | 13.1 [4.0; 60.6] | 0.016 | |
| Cytokeratin fragment 21-1 | 2.5 [1.8; 10.2] | 2.2 [1.2; 2.8] | 8.4 [2.5; 16.6] | 0.031 | |
| Pretreatment tumor volume (cm3) | 50.5 [18.1; 94.1] | 40.6 [15.2; 94.1] | 61.0 [30.9; 103.3] | 0.346 | |
FIGO—International Federation of Gynecology and Obstetrics; CCRT—concurrent chemoradiotherapy; DEG—differentially expressed genes; snoRNA—small nucleolar RNA. Continuous variables described using median [interquartile range] or mean ± standard deviation.